Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Sanofi (SNY - Analyst Report) received some encouraging news with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of its candidate, Lemtrada. The company is looking to get Lemtrada approved for the treatment of relapsing remitting multiple sclerosis (RRMS). Sanofi expects a final decision on Lemtrada by the European Commission (EC) in the next few months.

The CHMP issued a positive opinion on Lemtrada based on two pivotal phase III trials, which were completed in 2011. In the first study, CARE-MS I, Lemtrada met the first primary endpoint. Results showed that treatment with two annual cycles of Lemtrada as compared to Pfizer/Merck KGaA’s (PFE - Analyst Report)/(MKGAF) Rebif resulted in a 55% reduction in the relapse rate over the two-year span of the study.

In the second study, CARE-MS II, Lemtrada met both the primary endpoints. Results showed that treatment with Lemtrada resulted in a 49% reduction in the relapse rate compared to Rebif, over a two-year period.  Additionally, Lemtrada showed a 42% reduction in the risk of sustained accumulation (worsening) of disability.

We remind investors that Lemtrada is also under review for the above mentioned indication in the US. The US Food and Drug Administration is expected to render a decision on Lemtrada’s marketing application towards the end of this year.

Apart from issuing a positive opinion on Lemtrada, CHMP also recommended a new active substance (NAS) designation for another RRMS drug, Aubagio.

We are pleased with Sanofi’s efforts to develop its pipeline, which should fetch significant revenue contributions upon approval. We believe that the pipeline at Sanofi must deliver, since many of its drugs are facing generic competition.

Sanofi, a large-cap pharma company, carries a Zacks Rank #3 (Hold). However, other large cap pharma stocks such as Novo Nordisk (NVO - Analyst Report) currently look more attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%